Comparison of single-pill strategies first line in hypertension: Perindopril/amlodipine versus valsartan/amlodipine

Journal of Hypertension

Volumn 33, Issue 2, 2015, Pages 401-411

  Mancia, Giuseppe ^a   Asmar, Roland ^b   Amodeo, Celso ^c   Mourad, Jean Jacques ^d   Taddei, Stefano ^e   Gamba, Marco Antonio Alcocer ^f   Chazova, Irina E ^g   Puig, Juan G ^h  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Foundation Medical Research Institute   (France)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^d AVICENNE HOSPITAL   (France)

^e UNIVERSITY OF PISA   (Italy)

^f Instituto de Corazon de   (Mexico)

^g INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

amlodipine; hypertension; perindopril; singlepill combination; valsartan

Indexed keywords

AMLODIPINE PLUS INDAPAMIDE PLUS PERINDOPRIL; AMLODIPINE PLUS VALSARTAN; VALSARTAN; AMLODIPINE; AMLODIPINE, PERINDOPRIL DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; INDAPAMIDE; PERINDOPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; AMLODIPINE; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; MIDDLE AGED; PERINDOPRIL; VALSARTAN;

EID: 84920873034     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000409     Document Type: Article

References (39)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics: 2013 update: a report from the American Heart Association. Circulation 2013; 127:e6-e245.
3. Vital signs: awareness and treatment of uncontrolled hypertension among adults: United States, 2003-2010. MMWR Morb Mortal Wkly Rep 2012; 61:703-709.
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2224-2260.
5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34:2159-2219.
6. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
7. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15; doi:1185/03007995.2014.964853.
8. National Institute for Health and Clinical Excellence. Hypertension: the clinicalmanagement of primary hypertension in adults. 2011. www.nice.org.uk. [Accessed 25 April 2014]
9. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
10. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
11. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345.
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
13. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
16. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370:829-840.
17. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898.
18. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159:795-802.
19. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of Renin-Angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124:128-135.
20. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29:563-580.
21. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
22. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
23. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536.
24. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156-161.
25. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
26. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051.
27. Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61:309-318.
28. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584-1590.
29. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58:566-572.
30. European Medicines Agency. Exforge (amlodipine/valsartan). Summary of product characteristics. Last updated 11 December 2013. www.ema.europa.eu. [Accessed 25 April 2014]
31. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
32. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
33. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55:399-407.
34. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs. individual component regimens. J Med Econ 2012; 15:897-905.
35. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59:1124-1131.
36. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension - a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone-system inhibitors involving 158,998 patients. Eur Heart J 2012; 33:2088-2097.
37. Mourad JJ, Le JS, Pirollo A, Mourad C, Gaudouen Y, Lopez-Sublet M. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. Curr Med Res Opin 2010; 26:2263-2276.
38. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Am J Hypertens 2001; 14:978-979.
39. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008; 24:3543-3557.